ABVD in MOPP-resistant Hodgkin's Disease. Annals of Internal Medicine 96: 139-144, 1982a

- Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. New England Journal of Medicine 306: 770-775, 1982b
- Schabel FM, Griswold DP, Corbett TH, et al. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 54: 1160-1167, 1984
- Skipper HE. Biochemical, biological, pharmacologic, toxicologic, kinetic and clinical (subhuman and human) relationships. Cancer 21: 600-610, 1968

Tura S, Mazza P, Gharlizoni F. High dose therapy followed by

autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. Scandinavian Journal of Haematology 37: 317-323, 1986

- van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. Journal of Clinical Oncology 7: 1776-1782, 1989
- Yi PI, Coleman M, Saltz L, Norton L, Topilow AA, et al. Chemotherapy for large cell lymphoma. A status update. Seminars in Oncology 17: 60-73, 1990

Correspondence and reprints: Dr D.J. Dodwell, Cookridge Hospital, Leeds LS16 6QB, England.

Errata

Vol. 42, No. 6, 1991, page 1042: The first sentence in section 4.2.2 should read 'In studies... had similar efficacy to norfloxacin 100 or 200mg 3 or 4 times daily...'.

Vol. 43, No. 5, 1992, page 728: The third paragraph in the right hand colum ('There has been a report... dexfenfluramine in humans.') should be omitted, as the information contained in it is already included in the succeeding paragraph.